정규장
Log in Sign up
JAGX
JAGX
Jaguar Health Inc
7월 28일 1:13 PM ET (한국 7/29 02:13)
$1.00
+0.04 ▲ +3.80%

재규어 헬스(JAGX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$5M
스몰캡
P/E
-
배당수익률
없음
52주 위치
0%
저점 +5% · 고점 -99%
애널리스트
적극 매수
C
Fundamental health
vs. 방어주 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 11%
밸류에이션
데이터 부족
재무 안정
Top 100%
Index -P/E -EPS (ttm) -708.72Insider Own 11.82%Shs Outstand 4.9MPerf Week -20.96%
Market Cap 0.00BForward P/E -EPS next Y -Insider Trans -Shs Float 4.3MPerf Month -63.37%
Enterprise Value 0.03BPEG -EPS next Q -Inst Own 0.15%Short Float 1.19%Perf Quarter -92.63%
Income -0.05BP/S 0.17EPS this Y -Inst Trans -0.55%Short Ratio 0.48Perf Half Y -96.27%
Sales 0.03BP/B -EPS next 5Y -ROA -76.77%Short Interest 0.05MPerf YTD -96.93%
Book/sh -38.11P/C 0.49EPS past 3/5Y 92.49% 85.33%ROE -370.95%52W High -98.92% ($92.75)Perf Year -98.72%
Cash/sh 2.05P/FCF -Sales past 3/5Y -1.26% 4.17%ROIC -52W Low 5.25% ($0.95)Perf 3Y -100%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 87.56%Gross Margin 77.88%Volatility(W/M) 16.13% 13.83%Perf 5Y -100%
Dividend TTM -EV/Sales 0.93Sales Y/Y TTM 155.96%Oper. Margin -86.26%ATR (14) 0.27Perf 10Y -100%
Dividend Ex-Date -Quick Ratio 0.3EPS Q/Q 97.67%Profit Margin -169.52%RSI (14) 20.63Recom 1
Dividend Gr. 3/5Y -Current Ratio 0.5Sales Q/Q 815.63%SMA20 -50.28% ($2.01)Beta -0.01Target Price $262.5
Payout -Debt/Eq -Earnings 2026/5/22SMA50 -61.66% ($2.61)Rel Volume 0.89Prev Close $0.96
Employees 47LT Debt/Eq -EPS/Sales Surpr. -SMA200 -96.08% ($25.51)Avg Volume(3M) 0.11MPrice $1
IPO 2015/5/13Option/Short No/YesTrades 426Volume 96,086Change 3.8%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $20M (YoY +816%) · 순이익 $9M (YoY +183%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Jaguar Health Inc (JAGX) Investment Analysis

What kind of company is Jaguar Health Inc?

재규어 헬스(JAGX) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

Jaguar Health () is a US-listed micro-cap pharmaceutical company that develops and sells gastrointestinal (GI) treatments based on the plant-derived compound Crofelemer. Its portfolio includes Mytesi for humans and Canalevia for companion animals, and the company has recently licensed out its US rights and is reshaping its business around the rare disease area of intestinal failure.

Learn more about Jaguar Health Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5671
Employees47people
IPO2015/05/13
Current Price$1.00 ≈ 1,370원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 22일 (금) · 장 마감 후
🔔 Earnings release 2026년 4월 7일 (화) · 장 시작 전

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-86.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-169.5%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
77.9%
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Top 32%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-370.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-76.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.50
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.30
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$262.50
현재가 대비 +26150.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+92.5%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median 30.0% · Top tier
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+85.3%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median 16.4% · Top tier
Past 5-Year Revenue
How much revenue grew over the past 5 years
+4.2%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 2.1% · Top 43%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+815.6%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median -4.5% · Top tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -168%p below the market
JAGX -100.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-168.3%p
Significantly behind the market
vs Health Care (XLV)
-124.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
-114.7%p
Significantly behind the market
vs Health Care (XLV)
-118.4%p
Significantly behind the sector average
Rank among peers
5-year return Lowest among peers Based on 245 peers
1-year return Lowest among peers Based on 315 peers
Current position within 52-week range
Low (-5.3%p) High (-98.9%p)
Current price is 5.3% above the 52-week low and 98.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-86.2%
Annualized volatility
534.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 80-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $1.00 below the midline ($2.01). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.446 < Signal -0.332 in negative zone + Hist negative (-0.113). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵
Current diagnosis · 2026-07-27
Oversold zone — rebound potential

RSI 24.4 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 5.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
0.17x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Top 1% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$262.50 vs. current price +26150.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Institutional modest net selling -0.6% · Short interest light 1.2% · Short interest fell -13.6%p over the last 87 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-0.6%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 0.1%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 11.8%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 88.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.2%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 87 days 📉 -13.6%p decrease
Short interest days to cover
0.5 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 4.9M주
Float (tradable shares) 4.3M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 87 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
JAGX JAGX This Stock
$4.9M- - -370.95% - +3.8%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 재규어 헬스(JAGX)?

재규어 헬스(JAGX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of JAGX?

The market cap of JAGX is approximately $5M, ranking 5,671 within its sector.

What is the 52-week high and low for JAGX?

JAGX has recorded a 52-week high of $92.75 and a low of $0.95.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.